NCT04164199

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 404 (actual)
• Sponsor: BeOne Medicines · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, extension study to evaluate the long-term safety and efficacy of BeiGene or BeOne investigational drugs in participants with advanced malignancies who participated in a prior BeiGene- or BeOne-sponsored clinical study (parent study).

Detailed description

For the purposes of this study, "study treatment" will refer to all investigational agents. A parent study is defined as the original BeiGene- or BeOne-sponsored clinical trial in which the participant was initially enrolled and received BeiGene or BeOne investigational drugs (with or without other treatments). Note: Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

Conditions

• Advanced Malignancies

Interventions

Type	Name	Description
DRUG	Tislelizumab	Administered intravenously.
DRUG	Pamiparib	Administered orally.
DRUG	Temozolomide	Administered orally.
DRUG	Sitravatinib	Administered orally.
DRUG	Ociperlimab	Administered intravenously.
DRUG	BAT1706	Administered intravenously.
DRUG	Fruquintinib	Administered orally.
DRUG	BGB-15025	Administered orally.
DRUG	Zanidatamab	Administered intravenously.
DRUG	BGB-A445	Administered intravenously.
DRUG	Surzebiclimab	Administered intravenously.
DRUG	Lenvatinib	Administered orally.
DRUG	LBL-007	Administered intravenously.

Timeline

• Start date: 2019-12-19
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2019-11-15
• Last updated: 2026-04-14

Locations

106 sites across 13 countries: United States, Australia, China, France, Italy, Japan, Malaysia, New Zealand, Poland, South Korea, Taiwan, Thailand, Turkey (Türkiye)

Regulatory

• FDA-regulated drug study